Elizabeth AllenResearch Associate II, Frontier Science Yanjie (Belle) BaoSenior Manager, Formulation Development James BarlowDirector of the Board Bio
Director of the Board
James Barlow is a member of the Board of Directors of North American Health Care, Inc., a privately held company that provides contractual services to facilities specializing in post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations (5 continents, 23 countries), financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. (NYSE:AGN), he oversaw financial due diligence, integration and structuring for more than 100 asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed and more than $4.5billion in other transactions. He ensured consistent application of all corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities.
Hari BhaskaranScientist II, RNA Sciences Arisa Iga CaleSr. Research Associate Giulio CattarossiSenior Research Associate, Translational Biology Lena CeballosSenior Research Associate, Analytical Development Brandon ChenAnalyst Investor Relations/Public Relations Pad ChivukulaCSO, COO Bio
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
ThanhChau DamSr. Research Associate, Translational Biology Jared DavisVP, Technical Operations & Manufacturing Peter FarrellChairman of the Board Bio
Chairman of the Board
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.
Jose GonzalesSr. Research Associate JP HeadleyAssociate Director, Accounting and Operations Michael HodgesR&D & Medical Consultant Dr. Ed HolmesDirector of the Board Bio
Dr. Ed Holmes
Director of the Board
Dr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. He became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, the SAB of Ajinomoto and Board of Directors of Tularik, Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine.
Dr. Steve HughesChief Development Officer Bio
Dr. Steve Hughes
Chief Development Officer
Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases. Prior to that he was Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of multiple drugs across several therapeutic areas. He has also held positions at Biogen Idec, CSL Behring and Sanofi. Dr. Hughes is Board Certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.
Daniel HwangAccounting Supervisor Priya KarmaliVP, Technology Innovation and Development Bio
VP, Technology Innovation and Development
Priya Karmali is Senior Director of Pharmaceutical Development at Arcturus Therapeutics Ltd. Dr. Karmali joined Arcturus in 2015 and is responsible for research and development efforts for LUNAR™ technology, Arcturus’ lipid mediated nucleic acid delivery system. She has over 15 years of experience in the field of lipid-based drug delivery systems from discovery to development. Prior to Arcturus, Priya was Associate Director of Formulation Development at Regulus Therapeutics where she led drug product development efforts for miRNA therapeutic drugs currently in various stages of clinical trials. Prior to joining Regulus, Priya was a Principal Scientist at Nitto Denko where she led formulation development efforts for their Vitamin A targeted siRNA lipid nanoparticle for treatment of liver fibrosis. Dr. Karmali has a Ph.D. in Chemistry from the Indian Institute of Chemical Technology where she specialized in development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She is an author or inventor on over 35 scientific publications and patents.
Jae Heon (Jay) KimResearch Associate I, Formulation Development Kristen KuakiniResearch Associate II Greg KubczakAssociate Director, Technical Services KC KummerfeldVice President, Finance & Corporate Controller Yi KuoResearch Associate II Allison LeeResearch Associate I, Formulation Development Robin LeeSenior Research Associate, Analytical Development Angel LeuSenior Research Associate, Frontier Science Pattraranee (Patty) LimphongAssociate Director, Drug Discovery Maher AlayyoubiScientist II, RNA Process Development Dr. Magda MarquetDirector of the Board Bio
Dr. Magda Marquet
Director of the Board
Dr. Magda Marquet is the co-founder and co-CEO of Alma Life Sciences, an investment and consulting firm with a portfolio of over twenty companies in the areas of diagnostics, digital health and pharmaceuticals, Chairman and co-Founder of Althea, an Ajinomoto company, and Co-founder of AltheaDx, a precision medicine company. She has three decades of experience in the biotechnology industry in the US and Europe. Prior to starting Althea, Dr. Marquet held management positions at Vical Inc., Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. She currently serves as a Board member for Sente, Independa and Portable Genomics. She is also co-Chairman of the Advisory Board of MD Revolution. Dr. Marquet was Chairman of BIOCOM (2013-2014) and is Chair of the Board of Visitors of the UCSD Moores Cancer Center. She serves as a Director of the Economic Development Corporation (EDC- Executive Committee) and of the Kyoto Symposium Organization. She is also a member of the UCSD Biological Sciences Dean Leadership Council and an advisor for the Chopra Foundation. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year Award in the Life Sciences category, the Athena Pinnacle Award and the Exemplary Service Award from the San Diego Business Journal. She is the first woman inducted in the Connect Entrepreneur Hall of Fame (2016) and the Director of the Year Award recipient (2016-Corporate Governance) from the Corporate Directors Forum.
Daiki MatsudaAssociate Director, Frontier Science Rajesh MukthavaramScientist II, Formulation Development Michelle NguyenResearch Associate II, Analytical Development Jocelyn TabaldoAdministrative Assistant Suezanne ParkerVice President, Translational Biology Paula PattersonSr. Research Associate, RNA Sciences Joseph E. PaynePresident & CEO, Director of the Board Bio
Joseph E. Payne
President & CEO, Director of the Board
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics Ltd. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Carlos Perez-GarciaSenior Scientist, Translational Biology Kumar RajappanPrincipal Scientist, Chemistry Janet ReedExecutive Assistant Josie RiveraResearch Associate I Neda SafarzadehDirector, Head of Investor Relations/Public Relations and Marketing Joseph RobertsAssistant Controller Scott RobertsAssociate Director, CMC Marciano SabladSenior Manager, Translational Biology Hazel SantosAccounts Payable Specialist Andrew SassineChief Financial Officer Bio
Chief Financial Officer
Andrew Sassine served on the Board of Directors of ICAD Inc. for two years. Mr. Sassine also serves on the board of directors of Nasdaq listed Gemphire Therapeutics, Inc.(GEMP), an early-stage cardiovascular drug company formed by a licensing agreement with Pfizer Inc. He also is Chairman of the Board of privately held ComHear Inc., a digital audio software and device company. Mr. Sassine previously served on the board of Acorn Energy, Inc, CNS Response, Inc. and FluoroPharma Medical, Inc., (FMPI). Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2004 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech between 2009 and 2014. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.
Kyle ScurlockSenior Accountant Kevin SkolSenior Vice President, Business Development & Alliance Management Ji Young SukAssociate Director, Translational Biology Kiyoshi TachikawaSenior Research Fellow, Frontier Science Wendy TaylorSenior Director, Program Management Ramon Diaz TrellesSenior Scientist, Frontier Science Jerel VegaManager, Formulation Production Lishuang (Lily) XuSenior Research Associate, Drug Discovery Rodrigo YelinSenior Program Manager Hyojung HongResearch Assistant, Formulation Development Donna MunozResearch Assistant, RNA Production Cristiano SacchettiScientist II, Translational Biology Tyler RaymerFacilities Manager Abraham GomezResearch Associate II, Translational Biology Mario OrnelasQuality Manager, Quality & Regulatory Claine SnowSr. IP & Transactions Counsel Brenda ClementeSenior Research Associate, Formulation Development Rob LopezFacilities-Shipping & Receiving Emily ChaoResearch Associate I, Frontier Science Jeff McQuistonPatent Agent Hannah HuynhLab Support Technician Mukunda KrishnaSenior Engineer, Technical Transfer Yi-Yu LinScientist II, Formulation Development Alana MontoyaSenior Research Associate, RNA Production Lisa Kiewag-ThompsonResearch Associate II, RNA Production Phuong-Danh TranResearch Associate I, Formulation Development Alex DailyPurchasing Manager Gloria ZhangResearch Associate I Sean SullivanExecutive Director, Process Development Pamela ReschExecutive Director, Quality and Regulatory Affairs Nadja El-MecharrafieResearch Associate II, Frontier Science Linda QuirinoResearch Associate II, Translational Biology Tim LugerResearch Associate II, RNA Process Development Cristine OhlsonContracts Administrator/Paralegal Yurong GuoSenior Manager, Analytical Development and QC Tyler SpencerSenior Financial Analyst Natasha BowmanVice President, Head of Human Resources
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.
March 27, 2020 Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System read more
March 11, 2020 Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results read more
March 4, 2020 Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology read more